GenKOre is focused on advanced gene therapy technologies, particularly in the development of treatments for genetic disorders such as Huntington's disease. The company is leveraging its proprietary "TaRGET" gene therapy platform, which utilizes a novel approach involving ultra-small gene editing tools. This technology aims to enhance the precision and efficiency of gene editing, potentially surpassing existing methods like CRISPR-Cas9 in terms of correction and delivery rates. GenKOre's commitment to innovation is further demonstrated by its selection for national drug development projects, which underscores the significance of its research in the biotechnology sector.

In addition to gene therapy, GenKOre is also involved in plant biotechnology, indicating a broader application of its technologies beyond human health. The company is actively engaged in research and development, with a focus on creating effective therapeutic solutions that address unmet medical needs. Their efforts are supported by a strong network of experts and collaborations, positioning GenKOre as a key player in the biotechnology landscape, particularly in the realm of deep science and advanced therapeutic modalities.

South Korea

Genkore is a Korea-based biotech company specializing in genetic scissors and gene therapy. They have developed a healthcare platform designed to provide gene therapy for medical emergencies that may occur in the future. The company has also announced collaborations with US-based companies for in vivo gene editing therapy and has signed deals worth up to $650M for gene editing tech. Genkore is also involved in plant biotechnology and has a strong focus on research and development.

GenKOre

Company Details